GZMB and neoplasm: The number of tumor infiltrated activated CD8+ T cell population (granzyme B, GZMB+/CD8+) significantly increased in Sunitinib treated mice compared to the vehicle group (from 32.3% to 53.1% (SUN‐LD), p < 0.05; or to 67.6% (SUN‐HD), p < 0.05; Figure 2F–G and Figure S2B, Supporting Information).